Chemomab Therapeutics (CMMB) Competitors $1.69 -0.05 (-2.87%) (As of 12/12/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CMMB vs. GNLX, ALXO, GNTA, NVCT, ASRT, EPRX, QNCX, ADAG, ELYM, and XFORShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Genelux (GNLX), ALX Oncology (ALXO), Genenta Science (GNTA), Nuvectis Pharma (NVCT), Assertio (ASRT), Eupraxia Pharmaceuticals (EPRX), Quince Therapeutics (QNCX), Adagene (ADAG), Eliem Therapeutics (ELYM), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Genelux ALX Oncology Genenta Science Nuvectis Pharma Assertio Eupraxia Pharmaceuticals Quince Therapeutics Adagene Eliem Therapeutics X4 Pharmaceuticals Chemomab Therapeutics (NASDAQ:CMMB) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations. Do insiders & institutionals have more ownership in CMMB or GNLX? 46.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 9.3% of Genelux shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor CMMB or GNLX? In the previous week, Genelux had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for Genelux and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.87 beat Genelux's score of 0.44 indicating that Chemomab Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Chemomab Therapeutics Very Positive Genelux Neutral Which has higher earnings and valuation, CMMB or GNLX? Chemomab Therapeutics has higher earnings, but lower revenue than Genelux. Genelux is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$24.22M-$1.00-1.69Genelux$8K10,879.47-$28.30M-$0.95-2.65 Is CMMB or GNLX more profitable? Chemomab Therapeutics' return on equity of -101.70% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -101.70% -76.18% Genelux N/A -105.05%-80.16% Do analysts rate CMMB or GNLX? Chemomab Therapeutics presently has a consensus target price of $7.33, suggesting a potential upside of 333.93%. Genelux has a consensus target price of $18.25, suggesting a potential upside of 624.21%. Given Genelux's higher probable upside, analysts plainly believe Genelux is more favorable than Chemomab Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more risk & volatility, CMMB or GNLX? Chemomab Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Genelux has a beta of -2.05, suggesting that its stock price is 305% less volatile than the S&P 500. Does the MarketBeat Community believe in CMMB or GNLX? Chemomab Therapeutics received 4 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 64.29% of users gave Chemomab Therapeutics an outperform vote. CompanyUnderperformOutperformChemomab TherapeuticsOutperform Votes1864.29% Underperform Votes1035.71% GeneluxOutperform Votes14100.00% Underperform VotesNo Votes SummaryChemomab Therapeutics beats Genelux on 10 of the 16 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.27M$6.85B$5.15B$9.23BDividend YieldN/A2.87%5.18%3.99%P/E Ratio-1.6911.06107.2517.76Price / SalesN/A217.471,299.58127.83Price / CashN/A22.7036.2235.66Price / Book1.105.274.894.89Net Income-$24.22M$152.46M$116.33M$225.53M7 Day PerformanceN/A-3.66%-1.58%-0.85%1 Month Performance-2.87%-4.54%0.00%3.89%1 Year Performance267.39%17.68%29.91%24.13% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics3.5896 of 5 stars$1.69-2.9%$7.33+333.9%+275.6%$24.27MN/A-1.6920Positive NewsGNLXGenelux1.4796 of 5 stars$2.70-0.4%$18.25+575.9%-80.1%$93.26M$170,000.00-2.8510Short Interest ↑ALXOALX Oncology3.805 of 5 stars$1.76+8.6%$10.67+506.1%-88.9%$92.82MN/A-0.6040News CoverageGNTAGenenta Science3.2373 of 5 stars$5.06-3.6%$25.00+394.1%+3.1%$92.55MN/A0.007Short Interest ↓Gap DownNVCTNuvectis Pharma3.2372 of 5 stars$4.73-2.9%$21.00+344.0%-44.6%$91.38MN/A0.008ASRTAssertio3.544 of 5 stars$0.95+0.5%$3.25+243.6%-9.4%$90.32M$152.07M0.0020Short Interest ↓EPRXEupraxia Pharmaceuticals3.0715 of 5 stars$3.31+6.1%$9.00+171.9%N/A$90.30MN/A0.0029Gap DownQNCXQuince Therapeutics1.7147 of 5 stars$2.05-2.4%$8.50+314.6%+104.2%$90.20MN/A0.0060Short Interest ↑ADAGAdagene1.9378 of 5 stars$2.03-1.5%$5.00+146.3%+17.2%$89.87M$18.11M0.00260Short Interest ↑Negative NewsHigh Trading VolumeELYMEliem TherapeuticsN/A$3.02+3.8%N/A+24.5%$89.85MN/A-5.7020Positive NewsXFORX4 Pharmaceuticals4.3502 of 5 stars$0.53+31.7%$2.88+447.0%-3.4%$89.64MN/A0.0080Options VolumeGap UpHigh Trading Volume Related Companies and Tools Related Companies GNLX Competitors ALXO Competitors GNTA Competitors NVCT Competitors ASRT Competitors EPRX Competitors QNCX Competitors ADAG Competitors ELYM Competitors XFOR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMMB) was last updated on 12/13/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMMB Stock Alerts